leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...7778798081828384858687...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. (Pubmed Central) -  Sep 21, 2022   
    Although FOLFIRINOX (L-Leucovorin/5-FU/Irinotecan/Oxaliplatin) is established as one of the standard therapies for patients with metastatic pancreatic cancer, the modified FOLFIRINOX (mFOLFIRINOX) is often used in clinical practice to reduce the incidence of toxicities...The incidences of severe neutropenia and FN in patients receiving mFOLFIRINOX in our clinical practice were comparable to previous reports. The risk factors for severe neutropenia in patients receiving mFOLFIRINOX were a low baseline white blood cell count and presence of heterozygosity for UGT1A1*28 or UGT1A1*6 polymorphism.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Retrospective data, Journal:  A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. (Pubmed Central) -  Sep 20, 2022   
    FOLFOX therapy is well tolerated and effective in patients with AGC initially presenting with DIC and subsequent second-line treatment might be crucial for better prognosis. ATRA plus FOLFOX4 significantly improves the overall survival and time to disease progression in patients with advanced HCC.
  • ||||||||||  MK-1084 / Merck (MSD)
    Enrollment change, Monotherapy:  A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) -  Sep 19, 2022   
    P1,  N=264, Recruiting, 
    Trial completion date: Sep 2024 --> Jun 2026 | Trial primary completion date: Sep 2023 --> Jun 2026 N=185 --> 264
  • ||||||||||  sirexatamab (DKN-01) / Leap Therap
    Enrollment open, Metastases:  DeFianCe: Phase 2 Study of DKN-01 in Colorectal Cancer (clinicaltrials.gov) -  Sep 19, 2022   
    P2,  N=150, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Herceptin (trastuzumab) / Roche, emavusertib (CA-4948) / Curis, Dr. Reddy's
    Trial completion date, Trial initiation date, Trial primary completion date:  CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (clinicaltrials.gov) -  Sep 16, 2022   
    P1,  N=42, Not yet recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Jul 2022 Trial completion date: Oct 2026 --> Jan 2027 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Dec 2025 --> Mar 2026
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
    Trial completion date, Combination therapy, Metastases:  CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Sep 16, 2022   
    P1/2,  N=49, Active, not recruiting, 
    Trial completion date: Oct 2026 --> Jan 2027 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Dec 2025 --> Mar 2026 Trial completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Review, Journal, BRCA Biomarker, IO biomarker:  Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. (Pubmed Central) -  Sep 14, 2022   
    The current treatment of metastatic PDAC in fit patients is based on two chemotherapy combinations (FOLFIRINOX and gemcitabine plus nab-paclitaxel) which were validated more than 8 years ago...This review evaluates the current expectations and limits of available treatments and analyses the existing trials. A permanent search for actionable vulnerabilities in PDAC tumor cells and microenvironments will probably result in a more personalized therapeutic approach, keeping in mind that supportive care must also play a major role if real clinical efficacy is to be achieved in these patients.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    P4 data, Journal:  A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer. (Pubmed Central) -  Sep 14, 2022   
    P3
    Ramucirumab [human vascular endothelial growth factor (VEGF) receptor-2 monoclonal antibody] + levofolinate, fluorouracil, and irinotecan (FOLFIRI) was approved for the treatment of metastatic colorectal cancer (CRC) in Japan based on the results from the phase 3 RAISE trial (NCT01183780)...Approximately 83.7% (n=303) and 25.4% (n=92) of patients had medication history of bevacizumab and anti-epidermal growth factor receptor (EGFR) antibodies, respectively...Although the current observational study enrolled patients with various medication history, the regimen of ramucirumab + FOLFIRI was manageable under clinical practice. No new safety concerns beyond the findings observed in previous clinical trials were reported.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Establishment of a human 3D pancreatic adenocarcinoma model based on a patient-derived extracellular matrix scaffold. (Pubmed Central) -  Sep 14, 2022   
    Finally, both PANC-1 and AsPC-1 cells cultured in 3D matrices showed a reduced response to treatment with FOLFIRINOX if compared to conventional bi-dimensional culture. Our 3D culture system with patient-derived tissue-specific decellularized ECM better recapitulates the pancreatic cancer microenvironment compared to conventional 2D culture conditions and represents a relevant approach for the study of pancreatic cancer response to chemotherapy agents.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) -  Sep 14, 2022   
    P2,  N=28, Recruiting, 
    The MEND-IT study aims to evaluate the CR rate after intensified chemotherapy prior to concomitant chemoradiotherapy in a homogeneous group of patients with locally advanced rectal cancer and indisputably unfavourable characteristics, defined as hr-LARC, in order to improve their prognosis. Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    A CASE OF FATAL FOLINIC ACID, FLUOROURACIL, AND OXALIPLATIN (FOLFOX)-INDUCED PNEUMONITIS (Convention Center Exhibit Hall: Rapid Area 2D) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3773;    
    FOLFOX related pulmonary toxicity is a rare but potentially lethal complication. Data concerning mechanism of injury and optimal therapy is limited, warranting further investigation.
  • ||||||||||  oxaliplatin / Generic mfg., capecitabine / Generic mfg.
    CORONARY VASOSPASM FROM COMBINATION CAPECITABINE AND OXALIPLATIN THERAPY (Convention Center Exhibit Hall: Rapid Area 4C) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3704;    
    Within one hour of administration of FOLFOX, he developed ST segment elevations that resolved with nitroglycerin... Capecitabine, with or without, oxaliplatin increases the risk of chemotherapy-induced cardiotoxicity, specifically coronary vasospasm, which can present as acute coronary syndrome.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    INVASIVE FUNGUS AMONG US: A RARE CASE OF CEREBRAL PHAEOHYPHOMYCOSIS (Convention Center Exhibit Hall: Rapid Area 3D) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3495;    
    The invasive fungus C. Bantiana carries a high mortality rate. Any evidence of this organism must raise concern in immunocompromised individuals and empiric treatment should not be delayed.